Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 13/20 | 0.56 |
| ▸ | TACR1 | P25103 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630653 | 0.95 | TACR2 (0.54) | TACR2TACR1ALDH1A1TP53TACR3 | |
| Hydrochloric Acid SCHEMBL7750460 | 0.95 | TACR2 (0.53) | TACR2TACR1ALDH1A1TP53TACR3 | |
| SCHEMBL4935551 | 0.91 | TACR2 (0.53) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL29536190 | 0.90 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL2990201 | 0.90 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4944052 | 0.90 | TACR2 (0.52) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL4553408 | 0.90 | TACR2 (0.56) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4941130 | 0.89 | TACR2 (0.55) | TACR2TACR1TACR3CYP3A4CYP2D6 | |
| SCHEMBL6469489 | 0.82 | TACR2 (0.70) | TACR2TACR1ALDH1A1TP53TACR3 | |
| SCHEMBL4630059 | 0.81 | TACR2 (0.57) | TACR2TACR1TACR3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1395582-B1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-05-04 | — | — | EP | disclosed |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1395582-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094821-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TACR2, TACR1, KIT | TACR2 1/4885TACR1 2/4885ALDH1A1 2079/4885 |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | KIT, TACR2, P2RX3 | TACR2 2/4885TACR1 4/4885ALDH1A1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.